These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31272567)

  • 1. Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
    Iakobishvili Z; Hasin T; Klempfner R; Shlomo N; Goldenberg I; Brenner R; Kornowski R; Gerber Y
    Mayo Clin Proc; 2019 Jul; 94(7):1171-1179. PubMed ID: 31272567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
    Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A;
    Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
    Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
    Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.
    Haim M; Benderly M; Brunner D; Behar S; Graff E; Reicher-Reiss H; Goldbourt U
    Circulation; 1999 Aug; 100(5):475-82. PubMed ID: 10430760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
    Goldbourt U; Behar S; Reicher-Reiss H; Agmon J; Kaplinsky E; Graff E; Kishon Y; Caspi A; Weisbort J; Mandelzweig L
    Am J Cardiol; 1993 Apr; 71(11):909-15. PubMed ID: 8465780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
    Tenenbaum A; Boyko V; Fisman EZ; Goldenberg I; Adler Y; Feinberg MS; Motro M; Tanne D; Shemesh J; Schwammenthal E; Behar S
    Cardiovasc Diabetol; 2008 Jun; 7():18. PubMed ID: 18565233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study.
    Tanne D; Benderly M; Goldbourt U; Boyko V; Brunner D; Graff E; Reicher-Reiss H; Shotan A; Mandelzweig L; Behar S;
    Am J Med; 2001 Oct; 111(6):457-63. PubMed ID: 11690571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
    Bezafibrate Infarction Prevention (BIP) study
    Circulation; 2000 Jul; 102(1):21-7. PubMed ID: 10880410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association of Body Mass Index and 20-Year All-Cause Mortality Among Patients With Stable Coronary Artery Disease.
    Younis A; Younis A; Goldkorn R; Goldenberg I; Peled Y; Tzur B; Klempfner R
    Heart Lung Circ; 2019 May; 28(5):719-726. PubMed ID: 29581037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.
    Tanne D; Koren-Morag N; Graff E; Goldbourt U
    Circulation; 2001 Dec; 104(24):2892-7. PubMed ID: 11739302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
    Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
    Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.
    Younis A; Younis A; Tzur B; Peled Y; Shlomo N; Goldenberg I; Fisman EZ; Tenenbaum A; Klempfner R
    Cardiovasc Diabetol; 2016 Oct; 15(1):149. PubMed ID: 27793156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
    Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
    J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.